The reversal of the order resulted in T cell activity at half the potency and one-seventh the antibody levels, the latter still five times higher than two doses of Oxford—AstraZeneca.
Newer research from the AstraZeneca trials showed that people had better protection if dose 2 was given closer to 12 weeks.
Analysis of reported after vaccination with Oxford—AstraZeneca, and vaccines, found a temporally related incidence of 0.